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Background: Basaloid squamous cell carcinoma presents with a preference for the head and neck region, and
shows a distinct aggressive behavior, with frequent local recurrences, regional and distant metastasis. The
alterations in the cadherin-catenin complex are fundamental requirements for the metastasis process, and this is
the first study to evaluate the immunostaining of E-cadherin and β-catenin in oral basaloid squamous cell
carcinoma.
Methods: Seventeen cases of this tumor located exclusively in the mouth were compared to 26 cases of poorly
differentiated squamous cell carcinoma and 28 cases of well to moderately differentiated squamous cell carcinoma
matched by stage and tumor site. The immunostaining of E-cadherin and β-catenin were evaluated in the three
groups and compared to their clinicopathological features and prognosis.
Results: For groups poorly differentiated squamous cell carcinoma and basaloid squamous cell carcinoma,
reduction or absence of E-cadherin staining was observed in more than 80.0% of carcinomas, and it was statistically
significant compared to well to moderately differentiated squamous cell carcinoma (p = .019). A strong expression
of β-catenin was observed in 26.9% and 20.8% of well to moderately differentiated squamous cell carcinoma and
poorly differentiated squamous cell carcinoma, respectively, and in 41.2% of basaloid squamous cell carcinoma. The
5-year and 10-year overall and disease-free survival rates demonstrated no significant differences among all three
groups.
Conclusions: The clinical and biological behavior of three groups of the oral cavity tumors evaluated are similar.
E-cadherin and β-catenin immunostaining showed no prognostic value for basaloid and conventional squamous
cell carcinomas.
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The basaloid squamous cell carcinoma (BSCC) is consid-
ered an aggressive variant from the squamous cell car-
cinoma, initially identified and meticulously described in
head and neck area by Wain et al. [1]. This malignant
neoplasm presents a predilection for the upper aerodiges-
tive tract, although it can be present in other locations
such as the lungs, esophagus, anal channel, and uterus
[2,3]. In the mouth, these tumors have been identified in
the floor of the mouth [4,5], tongue [5], buccal mucosa
[6,7], gingiva [5,7], retromolar trigone [8], soft palate and
oropharynx [2].
In head and neck area, BSCC is considered aggressive
based mainly on clinical behavior, with frequent local
recurrences, as well as regional and distant metastasis
[9]. Some studies compared the clinical and/or biological
evolution of this malignant neoplasm and of the conven-
tional squamous cell carcinoma (SCC) [10,11]. However,
the determination of the aggressive biological behavior
of the SCC of head and neck has been based not only
on the evaluation of the clinical aspects but mainly on
the potential of cellular proliferation and tissue invasion,
as well as on the loss of the expression of the molecules
of adhesion of the epithelial neoplastic cells.
The alterations in the molecules of cellular adhesion
in the SCC, mainly those associated with the cadherin-
catenin complex [12-14] are fundamental requirements
for the metastasis process, determining a more aggressive
biological behavior and an unfavorable clinical evolution
for these tumors [15]. The influence of the altered expres-
sion of the adhesion molecules in the clinical tumoral
behavior of conventional SCCs with different degrees of
cellular differentiation is an aspect frequently investigated
[15-21]; however, to the best of our knowledge, the immu-
nohistochemical expression of E-cadherin and β-catenin
in oral BSCCs has not been reported. Thus, the purpose of
this study was to assess the expression of E-cadherin and
β-catenin in oral BSCCs, well to moderately differentiated
SCCs (W/MSCC) and poorly differentiated SCCs (PDSCC),
and compare the immunostaining of the two markers to
their clinicopathological features and prognosis.
Methods
Patients
The oral BSCCs, W/MSCCs and PDSCCs used in this
study are from the sample bank of the Pathology and
Head and Neck Surgery and Otorhinolaryngology De-
partments of A. C. Camargo Cancer Hospital, diagnosed
between 1970 and 2000. The 17 BSCCs and 26 PDSCCs
have been previously analyzed by Sampaio-Goes et al.
[22], and the 28 W/MSCCs were matched by clinical
stage and tumor site with PDSCCs. All patients in-
cluded in this retrospective study underwent surgical
treatment of the primary oral carcinoma and postoperativeradiotherapy and/or chemotherapy. The inclusion criteria
were (1) diagnosis of SCC of the tongue, floor of the
mouth, inferior gingiva, or retromolar area confirmed
by biopsy; (2) patients not previously treated for any
neoplasm; and (3) curative surgery as the first treat-
ment. Exclusion criteria were (1) inoperable disease or
unresectable tumors; (2) distant metastases at the time
of admission; (3) presence of other primary tumors;
(4) patients who refused surgical treatment.
The patients’ data were collected from the medical re-
cords and included sex, age, ethnic group, tobacco and/or
alcohol consumption, tumor location and size, evidence of
nodal metastases, T and N stage, treatment (surgery, post-
operative radiotherapy, and/or adjuvant chemotherapy),
and clinical follow-up (recurrence, occurrence of a second
primary tumor, and death).
Cases were included in this study after three patholo-
gists (JACH, DTO, GL) reevaluated the hematoxylin-eosin
and periodic acid-Schiff (PAS) − stained sections from ex-
cised primary tumor specimens. Histopathological analysis
was performed on the invasive tumor front in all cases.
The tumor front was defined as the most advanced 3-6
tumor cell layers of a given tumor according to Piffko
et al. [23]. Histopathological malignancy grading of the
invasive tumor front was performed according to criteria
described by Bryne et al. [24].
The study was approved by the Research Ethics Com-
mittee of A. C. Camargo Cancer Hospital (protocol
#497/03). The authors read the Helsinki Declaration
and followed the guidelines in this investigation.
Immunohistochemistry
Formalin-fixed, paraffin-embedded 3-μm sections were
cut from the oral BSCCs and SCCs for immunohisto-
chemistry analysis with monoclonal anti-E-cadherin
(36 clone, BD Transduction, ref C20820, Franklin Lakes,
USA) and anti-β-catenin (14 clone, BD Transduction, ref
C19220, Franklin Lakes, USA). Immunohistochemical
staining was performed using a standard streptavidin-
biotin-peroxidase complex method (StreptABComplex/
HRP, Duet Mouse/Rabbit, Dako ref K0492, Glostrup,
Denmark). After antigen retrieval with 10 mM citrate
buffer, pH 6.0, in a pressure cooker, endogenous perox-
idase activity was blocked by incubation in 3% H2O2 for
20 minutes. The sections were incubated overnight at 4°C
with the following primary antibodies and dilutions:
E-cadherin (1:700) and β-catenin (1:1000) in bovine
serum albumin (BSA) solution to block a nonspecific reac-
tion. The antigen − antibody reaction was visualized using
3’3 diaminobezidine tetrahydrochloride 60 mg% (DAB/
SIGMA, ref D-5637, St. Louis, MO). Sections were
counterstained with Harris hematoxylin before being
dehydrated and cover slipped. Dermatofibroma and a
fragment of intestine served as positive control for E-
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control, the primary antibody was omitted during the
immunohistochemical staining.
Immunostaining quantification
For each case, 10 non-overlapping fields (107.040.116 μm2)
at 400X magnification of invasive tumor front were
digitally captured with a Samsung camera attached to a
light microscope (Axioskop2 plus, Zeiss, Jena, Germany)
and recorded by Image Lab computer program system.
The images in each slide of E-cadherin and β-catenin anti-
bodies were assessed by semiquantitative score method as
previously instituted in oral BSCC and SCC by Sampaio-
Goes et al. [22], based on the sum of the proportion of
immunopositive tumor cells, the intensity of the expres-
sion of markers used and cellular location (membranous
or cytoplasmic and nuclear) of immunostaining.
The rate of positive tumor cells was divided into three
groups:
 0 = ≤ 10% of positive tumor cells;
 1 = 11 a 50% of positive tumor cells;
 2 = >50% of positive tumor cells.
The intensity of immunostaining was evaluated as
follows:
 0 = without immunostaining;
 1 = weak immunostaining;
 2 = strong immunostaining.
The cellular location of immunostaining was divided
into three groups:
 0 = without immunostaining;
 1 = cytoplasmic and nuclear immunostaining;
 2 = membranous immunostaining.
The sum of the scores, based on the proportion, the in-
tensity and cellular location of E-cadherin and β-catenin
was classified as:
 0–4 = Score 1 = absent or weak immunostaining;
 5–6 = Score 2 = strong immunostaining.
Immunostaining results were evaluated by three inves-
tigators (JACH, GL, DTO) without prior knowledge of
the tumor's histopathologic features and the patient's
clinical status. The cases of incongruence were reviewed
for a final consensus.
Statistical analysis
First, to verify the differences between the mean ages,
the Student’s t-test was used and, subsequently, the agevariable was categorized. The Fisher exact test or chi-
square test was used to assess the association between
demographic, clinical and microscopic variables, with a
significance level of 5%.
Survival rates (overall and disease-free survival), assessed
at 5 and 10 years, were calculated by the Kaplan − Meier
method. Comparisons among survival curves were verified
by the log-rank test with a significance level of 5%.
Results
The clinical and demographic parameters of patients
with oral BSCC and conventional oral PDSCC or W/
MSCC were similar, as summarized in Table 1.
Cytoplasmic and membranous E-cadherin expression
was detected in the oral mucosa with a normal pattern
and in the tumor cells. A strong predominately mem-
branous expression of E-cadherin antibody was observed
in more than 40% of W/MSCCs. In the PDSCC and
BSCC groups, 19% and 12% of the specimens, respect-
ively, showed a strong cytoplasmic immunostaining for
E-cadherin (Table 2). Furthermore, in the BSCCs, the
membranous expression of E-cadherin was observed in
only a few rare tumors (Figure 1).
In addition to E-cadherin, the expression of β-catenin
showed nuclear, cytoplasmic and membranous immu-
nostaining in tumor cells. Weak immunostaining for
β-catenin was detected in over 70% of both groups of
SCCs (PDSCC and W/MSCC) and in 59% of BSCCs.
Strong immunostaining for β-catenin antibody was
observed in only 28% and 23% of W/MSCC and PDSCC
groups, respectively (Table 2). In BSCCs, membranous ex-
pression of β-catenin, although irregular, was detected
along with cytoplasmic and nuclear expression in 41% of
the specimens (Figure 2).
A statistically significant difference in the expres-
sion of E-cadherin in tumor cells was observed in the
W/MSCC group compared with BSCC and PDSCC
groups (p = .019). However, no statistically significant
difference was found between the three different groups
of carcinomas studied with regard to epithelial expres-
sion of β-catenin (Table 2).
In addition to clinically detected positive lymph nodes,
no statistically significant correlation between micro-
scopically confirmed positive lymph nodes (pN) and E-
cadherin and β-catenin immunostaining was established
in the three SCC groups studied. However, patients with
positive lymph nodes at diagnosis had a twofold increase
in the relative risk of death (p = .025). The comparison
between the curves of overall survival and disease-free
survival showed no statistically significant differences be-
tween BSCC, PDSCC and W/MSCC groups (Figures 3
and 4). Also there was no difference between the overall
and disease-free survival rates, regarding immunostain-
ing for E-cadherin and β-catenin, for all the patients.
Table 1 Distribution of the clinical features of patients
with oral BSCC, W/MSCC and PDSCC
Clinical features No. of cases (%)
BSCC PDSCC W/MSCC p value*
Sex
Male 15 88.2 25 96.1 26 92.9 NA
Female 2 11.8 1 3.9 2 7.1
Ethnic group
White 15 88.2 22 84.6 24 85.7 NA
Non-White 2 11.8 4 15.4 4 14.3
Age, y
≤ 59 7 41.2 15 57.7 16 57.1 .504
> 59 10 58.8 11 42.3 12 42.9
Tobacco#
Yes 12 85.7 22 91.7 22 88.0 NA
No 2 14.3 2 8.3 3 12.0
Alcohol#
Yes 10 76.9 21 87.5 22 88.0 NA
No 3 23.1 3 12.5 3 12.0
Clinical T classification
T1 − 2 5 29.4 6 23.1 9 32.1 .754
T3 − 4 12 70.6 20 76.9 19 67.9
Clinical N classification
N0 5 29.4 8 30.8 9 32.1 .981
N1 − 2 − 3 12 70.6 18 69.2 19 67.9
Tumor site
Tongue 3 17.7 5 19.3 7 25.0 NA
Floor of mouth 10 58.8 9 34.6 8 28.6
Retromolar/gingiva 4 23.5 12 46.1 13 46.4
Neck dissection
Without 0 0.0 0 0.0 1 3.6 NA
Ipsilateral 9 53.0 19 73.0 22 78.6
Bilateral 8 47.0 7 27.0 5 17.8
Radiotherapy
Yes 15 88.2 22 84.6 18 64.3 NA
No 2 11.8 4 15.4 10 35.7
Chemotherapy
Yes 3 17.7 7 26.9 5 17.9 NA
No 14 82.3 19 73.1 23 82.1
Total 17 100 26 100 28 100
Abbreviations: BSCC basaloid squamous cell carcinoma, PDSCC poorly
differentiated squamous cell carcinoma, W/MSCC well to moderately
differentiated squamous cell carcinoma, NAnot applicable.
*Analysis by chi-square test at 5% significance level.
#Excluding patients with lost records.
Table 2 Immunohistochemical analysis of patients with
oral BSCC, W/MSCC and PDSCC
Antibodies No. of cases (%)
BSCC PDSCC W/MSCC p value*
E-cadherin
Weak immunostaining 15 88.2 21 80.8 15 53.6 .019
Strong immunostaining 2 11.8 5 19.2 13 46.4
β-catenin
Weak immunostaining 10 58.8 20 76.9 20 71.4 .355
Strong immunostaining 7 41.2 6 23.1 8 28.6
Total 17 100 26 100 28 100
Abbreviations: BSCC basaloid squamous cell carcinoma, PDSCC poorly
differentiated squamous cell carcinoma, W/MSCC well to moderately
differentiated squamous cell carcinoma.
*Analysis by chi-square test at 5% significance level.
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BSCC has been considered an aggressive variant of SCC
at different anatomic sites [7]; however, a comparative
study [25] between these two neoplasias in the oral
cavity have included samples with a small number of
patients, which precludes reliable comparisons of the
clinical and biological behavior between oral BSCC and
SCC. The comparative analysis of the BSCCs, PDSCCs
and W/MSCCs revealed demographic and clinical results
similar to those described in the literature [26-28]; these
tumors occurred mainly in male patients with a mean age
of 58 years, being consumers of tobacco and alcohol.
Regarding the clinical behavior, we found that the
highest rate of local recurrence occurred in the PDSCC
group (38.5%) compared to BSCC and W/MSCC groups.
The rate of local recurrence for the BSCC was 17.7%,
which is similar to rates found by other authors [2,29]. A
higher frequency of regional recurrence and distant me-
tastasis was detected in the BSCC group than the PDSCC
group, in agreement with Fritsch et al. [30], suggesting a
more aggressive clinical profile for BSCC. The lungs were
the most commonly affected site by both metastatic
neoplasms. No patient of the W/MSCC group developed
distant metastases, and the regional recurrence rate of this
group was similar to that observed for the BSCC.
Besides the clinical and morphological characteristics
of malignancy, the expression of cell adhesion molecules
is fundamental to the design of the biological behavior
of tumors. The cell adhesion molecules E-cadherin and
β-catenin are responsible for the maintenance of inter-
cellular unions associated with the process of tumor in-
vasion and metastatic spread in SCCs. The reduction or
loss of expression of the cadherin-catenin complex via
mutations or loss of heterozygosity occurs frequently
during carcinogenesis, affecting its tumor suppressor ac-
tivity [12-14,31]. As the BSCC is considered a variant
from the SCC [7], the role of E-cadherin and β-catenin
in the pathogenesis of BSCC may be similar to SCC.
Figure 1 Immunostaining for E-cadherin. A) Immunostaining for E-cadherin in normal oral mucosa. B) Strong membranous immunostaining in
the oral basaloid squamous cell carcinoma (BSCC). C) Most neoplastic cells of well to moderately differentiated squamous cell carcinoma (W/MSCC)
showed strong membranous immunopositivity. D) Poorly differentiated squamous cell carcinoma (PDSCC) showed weak membranous
immunostaining. (A, B, C and D, immunohistochemistry E-cadherin; original magnifications, A, B and D, ×400; C, ×100).
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has been more clearly verified in well-differentiated
SCCs, which maintain their cell adhesiveness and are
less invasive compared with PDSCCs with an infiltrative
invasion pattern and little or no cell cohesion [15,20].
E-cadherin showed weaker immunostaining for BSCC
than W/MSCC, but there is no difference between theFigure 2 Immunostaining for β-catenin. A) Immunostaining for β-caten
cytoplasmic and nuclear immunopositivity. B) Well to moderately differenti
cytoplasmic and nuclear immunopositivity. C) Poorly differentiated squamo
and nuclear immunostaining. (A-C, immunohistochemistry β-catenin; originimmunostaining for BSCC and PDSCC, suggesting that
the BSCC may present the similar biological behaviour
to PDSCC.
E-cadherin immunostaining compared to clinical features,
such as TNM stage, tumor location, local and regional re-
currence and distant metastasis, showed no statistically
significant difference in tumor groups analyzed. Howeverin in oral basaloid squamous cell carcinoma (BSCC) showed weak
ated squamous cell carcinoma (W/MSCC) showed strong membranous,
us cell carcinoma (PDSCC) showed weak membranous, cytoplasmic
al magnifications, A-C, ×400).
Figure 3 Overall survival. Kaplan-Meier overall survival curves showing no statistically significant differences between overall survival of patients
with W/MSCCs, BSCCs and PDSCCs. W/MSCC, well to moderately differentiated squamous cell carcinoma; BSCC, basaloid squamous cell carcinoma;
PDSCC, poorly differentiated squamous cell carcinoma.
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sion of E-cadherin in SCCs with a higher frequency of re-
gional metastases. Regarding β-catenin, loss or reduced
expression was detected numerically in more than 70% of
SCCs and in 59% of BSCCs; however, no statistically sig-
nificant difference was detected when comparing the ex-
pression of this cell adhesion molecule between the three
tumor groups analyzed. These results agree with those of
Lopez-Gonzalez et al. [18] who also found a greater reduc-
tion in immunostaining for β-catenin in PDSCCs com-
pared to W/MSCCs of the larynx.
Catenins play a critical role in controlling cell adhesion
mediated by E-cadherin; this indicates that immunoreactivityFigure 4 Disease-free survival. Kaplan-Meier disease-free survival curves s
survival of patients with W/MSCCs, BSCCs and PDSCCs. W/MSCC, well to m
squamous cell carcinoma; PDSCC, poorly differentiated squamous cell carcidoes not always imply a normally functioning cadherin-
catenin complex [14]. Therefore, the influence of these
molecules in the process of invasion and metastasis should
be analyzed together [15-17,19,21], as in this study.
Patients with BSCC, PDSCC and W/MSCC of the oral
cavity in the present study showed, at diagnosis, an ad-
vanced clinical stage associated with a high frequency of
regional lymph node involvement. Study variable N con-
sisted of an independent factor indicative of unfavorable
prognosis of the three tumor groups studied. Patients with
positive lymph nodes at diagnosis had a twofold increase
in the relative risk of death (p = .025), regardless of age,
gender, tumor and immunoreactivity for E-cadherin andhowing no statistically significant differences between disease-free
oderately differentiated squamous cell carcinoma; BSCC, basaloid
noma.
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distant metastases, curves of overall survival and disease-
free survival showed no statistically significant differences
between BSCC, PDSCC and W/MSCC groups, similar to
Fritsch et al. [30], therefore oral BSCC demonstrated a
comparable prognosis to conventional SCC.
Conclusion
The results of this study do not verify that oral BSCCs
have a more aggressive clinical and biological behavior
than oral SCCs. E-cadherin and β-catenin immunostaining
showed no prognostic value for oral BSCCs, PDSCCs and
W/MSCCs matched by location and clinical stage.
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